cimetidine / Generic mfg. - LARVOL DELTA

Mitogenomic analysis and phylogenetic implications for the Deltocephalinae (Hemiptera: Cicadellidae). (PubMed, Invertebr Syst) - "Included members of the following tribes were consistently monophyletic: Athysanini, Chiasmini, Deltocephalini, Drabescini, Macrostelini, Paralimnini, Penthimiini, Scaphoideini and Stenometopiini. Consistent with other recent analyses, Fieberiellini, Goniagnathini and Penthimiini are early diverging lineages within Deltocephalinae. Overall, our results indicate that complete mitogenome sequences provide robust data for phylogenetic reconstruction."

Journal

Asparaginase-Associated Toxicities and Hypersensitivity Reactions in Pediatric and Adolescent Down Syndrome Patients with Acute Lymphoblastic Leukemia or Lymphoma (ASH 2023) - "Pegaspargase (PEG) is integral in protocols for the treatment of pediatric ALL and lymphoblastic lymphoma (LBL), and full exposure to all doses of PEG can be limited by toxicities, including hypersensitivity reactions (HSR) due to the production of anti-asparaginase antibodies rendering PEG therapy ineffective...An H1 blocker (diphenhydramine) and H2 blocker (ranitidine, famotidine or cimetidine) were administered prior to PEG administration in consolidation and subsequent cycles...Most toxicity occurred during the consolidation phase and no grade 4 or 5 toxicities were observed. Given the PEG-associated toxicity observed in DS ALL/LBL, we are conducting pharmacokinetic analysis to propose a lower dose of PEG which may minimize toxicity while maintaining therapeutic efficacy."

Clinical • Acute Lymphocytic Leukemia • Developmental Disorders • Genetic Disorders • Hematological Malignancies • Hepatology • Immunology • Leukemia • Lymphoma • Obesity • Oncology • Pediatrics

Glomerulus-Tubule Integrated Kidney-on-a-Chip Platform for Preclinical Evaluation of Chemotherapy-Induced Nephrotoxicity and Therapeutic Interventions (KIDNEY WEEK 2025) - "Nephrotoxicity was modeled by applying chemotherapeutic agents known to preferentially affect specific nephron segments: Cisplatin and Oxaliplatin predominantly affecting the tubule, and Sunitinib primarily targeting the glomerulus, each for 48 hours. Cimetidine, a tubule-protective agent, and Sildenafil, a glomerulus-targeted therapeutic, were administered to evaluate potential protective effects...Conclusion This study developed an integrated glomerulus-tubule kidney-on-a-chip and established chemotherapy-induced nephrotoxicity models. Therapeutic effects were experimentally validated using the chip, which shows promise as a preclinical tool for toxicity and drug efficacy evaluation."

Preclinical • Nephrology • AQP1

EGLN1-Positive Familial Erythrocytosis: A Rare Variant with an Unusually Aggressive Clinical Course (ASH 2024) - "These symptoms do not respond to cimetidine or hydroxyzine but are partially controlled to HCT targets well below 45%, with the best symptom relief at 38-40%.Furthermore, he has subsequently developed idiopathic inflammatory polyarthritis and interstitial pulmonary disease with exhaustive work up by rheumatology and pulmonology, respectively, returning negative for specific cause.ConclusionsThis case is the first clinical characterization of EGLN1 c.494del p(Pro165Glnfs*9) positive familial erythrocytosis. His refractory symptoms despite optimal hematologic control suggest that HCT level may be an inadequate indicator of disease control in familial erythrocytosis. As recognition, awareness, and testing of congenital JAK2 negative erythrocytosis increases, further research is needed to characterize the genotype and phenotype correlation for variants of this rare condition."

Clinical • Cardiovascular • Dermatology • Dyslipidemia • Fatigue • Fibrosis • Hematological Disorders • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Metabolic Disorders • Polycythemia Vera • Pruritus • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Rheumatology • Thrombosis • Venous Ulcer • CALR • EGLN1 • JAK2

Treatment of Dapsone-Induced Methemoglobinemia in a Transplant Recipient With Isosulfan Blue Allergy (ACG 2025) - "1 month post-LT, pneumocystis jirovecii pneumonia (PJP) prophylaxis was switched from sulfamethoxazole/trimethoprim (SMZ/TMP) to dapsone due to renal impairment...Dapsone was switched to atovaquone, which was not tolerated due to nausea; and was restarted 21 days later. Other medications included tacrolimus, cellcept and valcyte...Cimetidine use was weighed with balancing the risks for kidney injury due to acute interstitial nephritis with recent KT with improvement in MethHb.Figure: Figure 1. Methemoglobin Level after Cimetidine Initiation*Day of Cimetidine 400mg TID for 5 days initiation"

Clinical • Allergy • Anemia • Fatigue • Fibrosis • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Leukopenia • Metabolic Dysfunction-Associated Steatohepatitis • Nephrology • Pneumonia • Pulmonary Disease • Renal Disease • Respiratory Diseases • Transplantation • G6PD • HP

Erythema Annulare Centrifugum: A Dermatologic Suspicion for Malignancy (ACG 2025) - "Although the pathogenesis of EAC is not currently fully understood, it is commonly characterized as a hypersensitivity reaction that occurs in congruence with a multitude of different entities: infectious diseases (viruses, bacteria and parasites) and drugs (chloroquine, cimetidine, aceclofenac). It is of utmost importance for the PCP to recognize this malignant association, relay the importance of proper cancer screening, and refer the patient for a prompt dermatology follow-up. With an early detection of PEACE, the underlying cancer can be detected at an earlier stage of the disease ultimately resulting in a better long-term prognosis for the patient.Figure: Paraneoplastic Erythema Annulare Centrifugum Eruption shown on the torso from the initial presentationFigure: Resolution of previously seen Paraneoplastic Erythema Annulare Centrifugum Eruption after resection of his colorectal adenocarcinoma (as evidenced by abdominal surgical scar)"

Colorectal Adenocarcinoma • Colorectal Cancer • Dermatology • Immunology • Infectious Disease • Oncology • Solid Tumor

Structural basis of drug recognition by human MATE1 transporter. (PubMed, Nat Commun) - "To understand the molecular basis of drug recognition by hMATE1, we determined cryo-electron microscopy structures of the transporter in complex with the substrates 1-methyl-4-phenylpyridinium (MPP) and metformin and with the inhibitor cimetidine. Molecular dynamics simulations provide insights into the different binding modes and dynamic behaviour of the ligands within the pocket. Collectively, these findings define the structural basis of hMATE1 substrate specificity and shed light on its role in drug transport and drug-drug interactions."

Journal

Risk of Drug Induced Liver Injury with Use of Avacopan in ANCA Vasculitis - Results from Real-World Data (ACR Convergence 2025) - "Additionally, avacopan group had significantly higher use CYP3A4 inhibitors including itraconazole, ketoconazole, fluconazole, posaconazole, voriconazole, nirmatrelvir, ritonavir, amiodarone, diltiazem, cimetidine, and cyclosporine (all p < 0.05) (Table 2). In this matched cohort analysis, the incidence of DILI was low and comparable between patients treated with avacopan and those who were not. While no significant difference was observed, the limited number of events precludes definitive conclusions regarding comparative risk."

Clinical • Real-world • Real-world evidence • ANCA Vasculitis • Cardiovascular • Diabetes • Hepatology • Hypertension • Immunology • Infectious Disease • Inflammation • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Vasculitis

A rare case of hyperuricemia and acute kidney injury in a kidney transplant patient. (PubMed, Pediatr Nephrol) - "Subsequently, her uric acid remained low, suggesting the cessation of cimetidine maintained her baseline uric acid level. This case highlights the significance of monitoring uric acid levels post-transplant and the importance of attention to potential drug interactions."

Journal • Acute Kidney Injury • Dermatology • Dyslipidemia • Genetic Disorders • Metabolic Disorders • Nephrology • Obesity • Pediatrics • Renal Disease • Transplantation

Putative new biomarkers for renal transporter-mediated drug-drug interactions: Characterization as substrates of organic cation transporter 2, multidrug and toxin extrusion protein 1, and other important drug transporters. (PubMed, Drug Metab Dispos) - "Recently, we demonstrated that treatment with cimetidine, a classical OCT/MATE-inhibitor, decreased the renal excretion of serotonin, tyramine, 1-methylhistamine, 5-amino valeric acid betaine, and 4-guanidinobutanoic acid in humans...These transport proteins are known as important contributors to clinically observed drug-drug interactions. Of the respective 5 compounds, serotonin and 1-methylhistamine are the most promising candidates to be further investigated as biomarkers for interactions via OCT2/MATE1, which could improve drug-drug interaction assessment during clinical drug development."

Biomarker • Journal • Nephrology • SLC22A2

Perioperative Management of GLP-1 Receptor Agonists: A Review of U.S. vs International Guidelines (ASA 2025) - "Additionally, guidelines from France, Australia, and New Zealand advise perioperative administration of pharmacological agents, such as erythromycin, cimetidine with citrate, or other prokinetics to mitigate aspiration risk. The 2024 ASA guidelines recommend that GLP-1 RAs may be continued uninterrupted during the perioperative period for low-risk patients. Low-risk patients are defined as asymptomatic individuals who are in the maintenance phase of dosing, receiving lower or daily doses, and who lack additional risk factors for delayed gastric emptying. International guidelines vary considerably regarding the timing, necessity, risk stratification, and risk mitigation strategies associated with perioperative management of GLP-1 RAs."

Review • Anesthesia • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Use of cimetidine to enhance systemic acyclovir concentrations in patients with ineffective suppressive therapy for recurring herpes simplex virus infections: A novel purpose for an old drug. (PubMed, Br J Clin Pharmacol) - "We report a series of patients nonresponsive to suppressive valacyclovir therapy, explained by subtherapeutic acyclovir plasma levels. After a dose increase, or in some patients only after concomitant prescription of cimetidine, adequate levels were reached associated with significant clinical improvement."

Journal • Herpes Simplex • Infectious Disease

Function of histamine-driven cancer-associated fibroblast and hepatocyte growth factor in the progression of cholangiocarcinoma. (PubMed, Gastroenterol Rep (Oxf)) - "HIF-1α and FOSL1 played crucial roles in driving the proliferation, invasion, and migration of cholangiocarcinoma cells within the tumor microenvironment, orchestrated by CAFs. Furthermore, this study has provided theoretical support for the application of the HA receptor HRH2 inhibitor, Cimetidine, and the HGF receptor cellular mesenchymal-epithelial transition factor (c-MET) inhibitor, Capmatinib, in biliary tract tumors."

Journal • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • CAFs • FOSL1 • HGF • HIF1A • HRH2 • MET • MMP10

Quantifying Cell Membrane Permeability of Small to Mid-Size Drugs Using Quick Osmotic Cytoplasm Extraction. (PubMed, Anal Chem) - "To assess drug permeability, HeLa cells were incubated with three small-molecule drugs (propranolol, cimetidine, and atenolol) and one midsize drug (cyclosporin A) for 1-360 min. The calculated apparent influx/efflux permeability values and efflux ratios demonstrated distinct drug properties consistent with conventional reports. These results highlight the potential of CyTOR as a rapid, high-throughput method for assessing membrane permeability and intracellular drug retention."

Journal • CYTOR

Pancreatic panniculitis associated with presumed advanced pancreatic tumor: A case report and literature review. (PubMed, Pathol Res Pract) - "Despite sequential anti-infectives, glucocorticoids, Octreotide, Somatostatin, Ulinastatin, and Cimetidine, her condition deteriorated, culminating in death...Controlling panniculitis fundamentally requires treating the primary tumor: surgical resection (including metastases) significantly improves survival; platinum-based chemotherapy (e.g., FOLFOX/FOLFIRINOX) is preferred for ACC; and molecular profiling (BRCA/RAF/NTRK) guided targeted therapy is promising. Prognosis is poor; early recognition via clinician vigilance for unexplained panniculitis and pathologist identification of "ghost cells", coupled with multidisciplinary collaboration and aggressive tumor-directed therapy, is essential for improving outcomes."

Journal • Hepatology • Musculoskeletal Pain • Oncology • Pain • Pancreatic Cancer • Solid Tumor • BRCA • NTRK

Epidermodysplasia verruciformis pityriasis versicolor-like : two new family cases (EADV 2025) - "Treatment with Acitretin 1 mg/kg/d with photoprotection measures was initiated, resulting in stabilization of the disease...Several treatments have been tried (retinoids, interferon, cimetidine) with little or no reproducible success... This case highlights the importance of early diagnosis and management of EDV, including photoprotection and regular monitoring of precancerous lesions. Treatment options, ranging from pharmacological interventions to surgical excision, aim to reduce the risk of malignant transformation."

Clinical • Basal Cell Carcinoma • Dermatology • Infectious Disease • Non-melanoma Skin Cancer • Squamous Cell Carcinoma

A case of Amicrobial Pustulosis of Folds associated with Systemic Lupus Erythematosus (EADV 2025) - "Regarding treatment, Retinoids are effective in both conditions, but other therapeutic alternatives are considered first-line for APF, including systemic corticosteroids alone or in combination with acitretin or dapsone, dapsone alone, colchicine, cimetidine combined with ceftriaxone and vitamin C or zinc sulfate. Cyclosporine or methotrexate for refractory cases. Amicrobial pustulosis of the folds (APF) presents a diagnostic challenge, particularly when differentiating it from inverse pustular psoriasis. In our case, the patient had no personal or family history of psoriasis and is a young woman with known lupus, which favored the diagnosis of APF. Clinically, the pustules were localized exclusively to the folds, unlike inverse pustular psoriasis, where pustules or psoriasiform lesions can be found elsewhere."

Clinical • Dermatology • Dermatopathology • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Psoriasis • Pustular Psoriasis • Systemic Lupus Erythematosus

beneath the rash: histamine intolerance and skin disorders - what do we know so far? (EADV 2025) - "It is a multifactorial condition which can be caused by genetic polymorphism of both DAO and HNMT, DAO and HNMT deficiency whether acquired or reversible, dysbacteriosis, drugs including some anti-histamines (Cimetidine and dihydralazine)... Current evidence is highly suggestive of element of histamine intolerance in patients with atopic dermatitis and chronic idiopathic urticaria. Low histamine diet and diamine oxidase supplementation demonstrated a degree of efficacy in symptoms control of these conditions. It is highly advisable to check for histamine intolerance in patients presenting with atopic dermatitis and chronic idiopathic urticaria as HIT presents with unspecific symptoms and tends to be easily missed and underdiagnosed."

Atopic Dermatitis • Chronic Spontaneous Urticaria • Dermatitis • Dermatology • Immunology • Urticaria

Polypharmacy driven synergistic toxicities in elderly breast cancer chemotherapy drug management and adverse drug reactions: a mini review. (PubMed, Front Pharmacol) - "Age-linked gastric alkalisation, cytochrome-P450 attrition and renal decline compress pharmacokinetic space: cimetidine lifts epirubicin exposure by 39%, proton-pump inhibitors halve palbociclib troughs yet heighten neutropenia, and triazole antifungals quadruple free vincristine levels, yielding neuropathy in 87% of recipients. Beyond kinetics, overlapping end-organ liabilities-anthracycline-trastuzumab cardiotoxicity, taxane-β-blocker arrhythmia, capecitabine-warfarin haemorrhage-translate polypharmacy into a synergistic toxicity premium that erodes functional independence...Composite scores integrating regimen complexity with genomic risk and circulating toxicity markers are emerging as real-time sentinels. By weaving mechanistic, epidemiologic and implementation evidence, this review charts how polypharmacy propels synergistic toxicities in elderly breast-cancer chemotherapy and delineates stewardship frameworks poised to reconcile oncologic potency with geriatric..."

Adverse drug reaction • Journal • Review • Breast Cancer • Cardiovascular • Neutropenia • Oncology • Pain • Solid Tumor • DPYD

Ameliorative effects of Brassica oleracea var. viridis ethanol extract and fractions on cimetidine-induced reproductive toxicity in male Wistar rats. (PubMed, Front Vet Sci) - "viridis exhibits significant protective effects against cimetidine-induced reproductive toxicity through hormonal regulation, antioxidative mechanisms, and tissue preservation. The ethanol extract of Brassica oleracea (ELEBO) showed the most potent activity, supporting its potential use as a therapeutic adjunct in male infertility linked to pharmaceutical exposures."

Journal • Preclinical • Infertility • Sexual Disorders • CAT

Assessing Cytochrome P450 Drug Interaction Risk for Dordaviprone Using Physiologically Based Pharmacokinetic Modeling. (PubMed, CPT Pharmacometrics Syst Pharmacol) - "The simulated increase in dordaviprone AUC and Cmax (4.6- and 1.7-fold) following administration of multiple doses of itraconazole was consistent with the observed values (4.4- and 1.9-fold). All PBPK-simulated changes in dordaviprone plasma exposure when administered with CYP3A4 moderate (erythromycin, fluconazole) and weak (cimetidine) inhibitors, and moderate (efavirenz) and strong (rifampicin) inducers were consistent with their CYP3A4 potency classification (AUC ratio = 2.68, 2.48, 1.42, 0.35, and 0.17, respectively). The simulated AUC and Cmax of probe substrates for CYP3A4 (midazolam), CYP2C8 (repaglinide) and CYP2D6 (desipramine) after coadministration with 625 mg dordaviprone were the same as those in the absence of dordaviprone (ratio = 1.0) and remained unchanged after a sensitivity analysis using 10-fold more potent inhibition constants. Due to changes in dordaviprone plasma exposure when co-administered with CYP3A4 inhibitors, dordaviprone dose adjustments..."

Journal • PK/PD data • Brain Cancer • Glioma • Oncology • Solid Tumor

Cimetidine for Pediatric Use in Japan: Rising Prescriptions for a New Indication. (PubMed, Tohoku J Exp Med) - No abstract available

Journal • Pediatrics

Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Washington State University | Recruiting ➔ Completed | N=32 ➔ 16

Biomarker • Enrollment change • Trial completion

Targeting Fentanyl Pharmacokinetics to Reduce Fentanyl Withdrawal Severity: A Preclinical Evaluation of Cimetidine as a Potential Medication to Reduce Fentanyl Withdrawal (CPDD 2025) - "These preclinical results indicate that intravenously delivered cimetidine may be an easily-implemented and efficacious therapeutic to reduce fentanyl withdrawal severity in individuals with opioid use disorder undergoing fentanyl detoxification. Clinical evaluations of cimetidine as a fentanyl withdrawal therapeutic may be warranted."

PK/PD data • Preclinical • Addiction (Opioid and Alcohol) • Anesthesia • Substance Abuse

Bridging in vitro and clinical data: Experimental insights into the IC50 variability of dolutegravir as an organic cation transporter 2 inhibitor. (PubMed, Drug Metab Dispos) - "Similar uptake time dependency was observed with other inhibitors (cimetidine and pyrimethamine). However, the extent of variability differed among metformin, N1-methylnicotinamide, atenolol, frovatriptan, and sumatriptan, likely reflecting differences in cellular kinetics...DDI predictions using in vitro IC50 values suggested repeated dolutegravir administration could raise the area under the curve of OCT substrates, such as atenolol, nadolol, and sulpiride beyond regulatory thresholds...SIGNIFICANCE STATEMENT: This study identified experimental conditions affecting the IC50 variability of dolutegravir as an organic cation transporter 2 inhibitor. These findings offer valuable insights for improving in vitro to in vivo drug-drug interaction predictions and optimizing inhibition experiments for transporter-mediated drug-drug interactions."

Clinical data • Journal • Preclinical • SLC22A2